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Abstract
The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is characterized by congenital aplasia of
the uterus and the upper part (2/3) of the vagina in women showing normal development of
secondary sexual characteristics and a normal 46, XX karyotype. It affects at least 1 out of 4500
women. MRKH may be isolated (type I) but it is more frequently associated with renal, vertebral,
and, to a lesser extent, auditory and cardiac defects (MRKH type II or MURCS association). The
first sign of MRKH syndrome is a primary amenorrhea in young women presenting otherwise with
normal development of secondary sexual characteristics and normal external genitalia, with normal
and functional ovaries, and karyotype 46, XX without visible chromosomal anomaly. The
phenotypic manifestations of MRKH syndrome overlap with various other syndromes or
associations and thus require accurate delineation. For a long time the syndrome has been
considered as a sporadic anomaly, but increasing number of familial cases now support the
hypothesis of a genetic cause. In familial cases, the syndrome appears to be transmitted as an
autosomal dominant trait with incomplete penetrance and variable expressivity. This suggests the
involvement of either mutations in a major developmental gene or a limited chromosomal
imbalance. However, the etiology of MRKH syndrome still remains unclear. Treatment of vaginal
aplasia, which consists in creation of a neovagina, can be offered to allow sexual intercourse. As
psychological distress is very important in young women with MRKH, it is essential for the patients
and their families to attend counseling before and throughout treatment.
Disease name and synonyms
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome.
This syndrome is subdivided in two types: type I (isolated)
or Rokitansky sequence (OMIM 277000), and type II or
MURCS association (MÜllerian duct aplasia, Renal dys-
plasia and Cervical Somite anomalies) (OMIM 601076).
The MRKH syndrome is also referred to as CAUV (Con-
genital Absence of the Uterus and Vagina), MA (Müllerian
Aplasia) or GRES (Genital Renal Ear Syndrome). It would
thus be preferable that all entries (MRKH type I and type
II, MURCS association, CAUV, MA and GRES) refer to the
unique OMIM number 601076.
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Definition and diagnosis criteria
The MRKH syndrome is characterized by congenital apla-
sia of the uterus and the upper part (2/3) of the vagina in
women showing normal development of secondary sex-
ual characteristics and a normal 46, XX karyotype.
Other associated malformations include (type II or
MURCS association):
- Renal (unilateral agenesis, ectopia of kidneys or horse-
shoe kidney)
- Skeletal and, in particular, vertebral (Klippel-Feil anom-
aly; fused vertebrae, mainly cervical; scoliosis)
- Hearing defects
- More rarely, cardiac and digital anomalies (syndactyly,
polydactyly)
Isolated utero-vaginal aplasia is referred to as Rokitansky
sequence or to type I (isolated) MRKH syndrome. Incom-
plete aplasia and/or associated with other malformations,
is generally referred to as MURCS association (or type II
MRKH syndrome). In this case, the term GRES (Genital
Renal Ear Syndrome) can also be used.
Epidemiology
The incidence of MRKH syndrome has been estimated as
1 in 4500 female births [1-3]. The majority of cases
appears to be sporadic [4], however family cases have also
been described [1,5-7]. The mode of inheritance seems to
be autosomal dominant with an incomplete degree of
penetrance and variable expressivity [1,8,9], suggesting
that the prevalence of the syndrome may probably be
underestimated. Type I (isolated) MRKH is less frequent
than MURCS association [10].
Clinical description
Principle features of MRKH syndrome
The first clinical signal is generally a primary amenorrhea
in patients presenting with a normal female phenotype,
normal 46, XX karyotype [11-14], and normal and func-
tioning ovaries with no sign of androgen excess [15,16].
External examination reveals completed puberty with nor-
mal secondary female sexual characteristics (pubic hair
and breast development are Tanner stage 5) and normal
external genitalia. At the same time, the vagina is reduced
to a more or less deep (2–7 cm) vaginal dimple.
Anatomic examination is however necessary to diagnose
an MRKH syndrome of either type. Complete uterus apla-
sia in the presence of two rudimentary horns linked by a
peritoneal fold and normal Fallopian tubes correspond to
isolated or MRKH type I syndrome [17]. Type II MRKH is
characterized by uterine symmetric or asymmetric hypo-
plasia, accompanied by aplasia of one of the two horns or
by a size difference between the two horn rudiments, cou-
pled with tubar malformations such as hypoplasia or
aplasia of one or the two tubes [18].
Other malformations are often associated with MRKH
type II syndrome and involve the upper urinary tract, the
skeleton and the otologic sphere; heart malformations are
more rarely reported. In this case, the acronym MURCS is
generally used instead [13,19]. Cases of polycystic ovaries
[20-22] and ovarian tumors [23-25] have been described
in women presenting otherwise with normal 46, XX kary-
otypes. Moreover, aplasia or absence of Müllerian deriva-
tives suggestive of MRKH syndrome have been described
in cases of gonadal dysgenesis [26,27] or agenesis [28,29]
in XY or X0 patients presenting with female phenotypes.
At present, these types of ovarian pathologies are not con-
sidered to be part of the MRKH or MURCS clinical spec-
trum, since no single group of patients showing a random
association between any of these pathologies and utero-
vaginal aplasia has been reported so far. However, such
studies should be undertaken on large cohorts of women
with MRKH, to confirm this assumption.
Associated malformations in MRKH syndrome type II 
(MURCS association)
Associated upper urinary tract malformations
Altogether, associated upper urinary tract malformations
are found in about 40% of cases with MRKH syndrome
[18]. Mainly, they include unilateral renal agenesis (23–
28%), ectopia of one or both kidneys (17%), renal hypo-
plasia (4%), horseshoe kidney and hydronephrosis
[30,31]. Moreover, a case of bilateral renal agenesis (Pot-
ter sequence) associated with absence of uterus and ovi-
ducts has been reported in a medically aborted fetus [32],
reinforcing the idea that Müllerian aplasia, the principle
feature of MRKH syndrome, could be an extra manifesta-
tion of hereditary renal adysplasia (HRA) [8] in some
cases. At present, we are investigating a family where this
type of association has been found: the proband is a 46,
XX fetus with no visible chromosomal anomaly; the father
and his first daughter (now 5 years old) presented with
isolated unilateral renal agenesis. The father's cousin, in
addition, showed hemi-uterus, a feature already described
in HRA [33,34]. Taking this into account, renal adysplasia
seems to be either the prime characteristic of HRA where
Müllerian malformations of various types are sometimes
encountered or a secondary manifestation of MRKH syn-
drome. Although similar, these syndromes can probably
be distinguished from each other when family histories
are available: HRA is transmitted as a strict autosomal
dominant trait [35,36], whereas MRKH shows incomplete
penetrance coupled with a highly variable expressivity
when described in relatives [4,9,37,38]. It is thereforeOrphanet Journal of Rare Diseases 2007, 2:13 http://www.OJRD.com/content/2/1/13
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noteworthy that renal evaluation is not only required
when diagnosing MRKH syndrome, but is also fully justi-
fied in probands relatives.
Associated skeletal abnormalities
These anomalies mainly involve the spine (30 to 40%)
[18,30,39] and, less frequently, the face and the limb
extremities. Rachidial malformations encountered in
MURCS association are scoliosis (20%) [30], isolated ver-
tebral anomalies (asymmetric, fused or wedged verte-
brae), Klippel-Feil association (fusion of at least two
cervical segments, short neck, low hair line, restriction of
neck motion) [40] and/or Sprengel's deformity [41], rib
malformation or agenesis, and spina bifida [39]. Face and
limb malformations are mainly brachymesophalangy
[42], ectrodactyly [43], duplicated thumb [44], absent
radius [45], atrio-digital dysplasia (Holt-Oram like syn-
drome) [46,47] and facial asymmetry [48-50].
Associated hearing impairment
Auditory defects or deafness are associated with 10 to 25%
of MURCS patients [41,51,52]; they often concern con-
ductive deafness due to middle ear malformations, such
as stapedial ankylosis [41], or sensorineural defects of var-
ying severity [52]. Patients with hearing loss associated
with adysplasia of the auditory meatus and/or malformed
ears have also been reported [48,53].
Associated heart malformations
The association of MRKH with heart malformations is less
common. All reports involved lethal or severe cardiac
defects evocating Holt-Oram or velocardiofacial-like syn-
dromes requiring surgery when possible. Such reported
malformations were aorto-pulmonary window [47], atrial
septal defect [46] and conotruncal defects such as pulmo-
nary valvular stenosis [54] or Tetralogy of Fallot [55].
Etiology
The MRKH syndrome was initially considered to be of
sporadic occurrence, suggesting the involvement of non-
genetic or environmental factors [56] such as gestational
diabetes [57] or thalidomide-like teratogens [1,13,30,58].
However, studies analyzing available pregnancy histories
failed to identify any association with drug use, illness, or
exposure to known teratogens [57,59-61]. Another expla-
nation of the sporadic occurrence of the syndrome was the
hypothesizes of a polygenic/multifactorial inheritance
[4,38,56,62], characterized by a low recurrence risk for
first-degree relatives. The most plausible explanation actu-
ally relies on the description of significant and increasing
number of familial aggregates based on accurate delinea-
tion of the syndrome in the probands as well as in their
relatives. Indeed, utero-vaginal aplasia is often found
associated with other malformations, mainly renal and
skeletal, these two latter being sometimes observed in
combination with the first and interestingly, occurring in
more distant relatives as well as mothers of MRKH
patients [1,6,8,9,63]. Utero-vaginal aplasia can thus repre-
sent only one manifestation of a variably expressed
genetic defect. This latter appears to be transmitted as an
autosomal dominant trait with incomplete penetrance
coupled with variable expressivity of a single mutant gene,
as previously hypothesized [1,8,9,64], or of a limited
chromosomal imbalance undetectable in standard karyo-
types.
The etiology of MRKH syndrome has remained quite
unclear until now [64,65], although the spectrum of mal-
formations encountered suggests a developmental field
defect [13,19], involving organ systems which are closely
related during embryogenesis. More precisely, MRKH syn-
drome may be attributed to an initial affection of the
intermediate mesoderm, consequently leading (by the
end of the fourth week of fetal life) to an alteration of the
blastema of the cervicothoracic somites and the prone-
phric ducts [13]. These latter subsequently induce the dif-
ferentiation of the mesonephroi and then the Wolffian
and Müllerian ducts.
The lack of families with informative genetic histories has
initially led to a candidate gene approach for determina-
tion of the underlying etiology of the syndrome based
either on association with other genetic diseases or on
involvement during embryogenesis. As a result, the
genetic association of MRKH with galactosemia [66] or
with cystic fibrosis [67] was analyzed, but neither the gene
for galactose-1-phosphate uridyl transferase (GALT) [68]
nor the gene encoding the cystic fibrosis transmembrane
regulator (CFTR) chloride channel [67] showed any muta-
tion or polymorphism associated with the disorder. Aber-
rant expression of anti-Müllerian hormone (AMH) or its
receptor, both involved in Müllerian duct regression [69]
was hypothesized as a cause of MRKH syndrome [2,70];
however, this theory was later discounted as a result of
contradictory findings from a study of 32 patients [71].
Moreover, incomplete aplasia of Müllerian structures is
often observed in MRKH syndrome, showing that Mülle-
rian differentiation does take place but is incomplete.
Genes with a broad spectrum of activity during early
development (such as WT1 [72], PAX2 [73], HOXA7 to
HOXA13  [64,74] and PBX1  [74]) have also been sug-
gested as candidates, on the basis of phenotypes observed
in mutant mice. However, their role in MRKH syndrome
has not been subsequently demonstrated. WNT4  is
another developmental gene, belonging to the WNT fam-
ily of genes that regulate cell and tissue growth and differ-
entiation during embryogenesis [75]: its homozygotic
inactivation in the mouse model leads to a total failure of
Müllerian duct formation and numerous lethal defects atOrphanet Journal of Rare Diseases 2007, 2:13 http://www.OJRD.com/content/2/1/13
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birth [76]. In addition, WNT4 is known to be critical for
successful nephrogenesis [77-79]. A loss-of-function
mutation in the WNT4 gene has been recently described
in an 18-year-old woman, in association with absence of
Müllerian-derived structures, unilateral renal agenesis,
and clinical signs of androgen excess [80]. The congenital
malformations observed in this patient suggested an
MRKH-like phenotype and were similar to those observed
in the Wnt4-/-mouse [76], indicating a dominant effect
[80]. In this pathological case as well as in the mouse
model, it seems that loss-of-function of WNT4 which is
essential for normal ovarian differentiation [76], has led
to a masculinization of the fetal gonads consequently pro-
ducing androgens. The WNT4 protein is known to repress
male-specific genes such as those encoding steroidogenic
enzymes CYP17A1 and HSB3B2, which are essential for
the synthesis of testosterone [76]. Mutated WNT4 may not
be able to suppress the expression of androgen-synthesiz-
ing enzymes in ovarian cells, therefore leading to the
observed hyperandrogenic phenotype [80,81]. Further-
more, WNT4 appears to be essential for the initial differ-
entiation of the Müllerian ducts [65,76,82]. The
dominant-negative mutation of WNT4 may then produce
two distinct effects, hyperandrogenism and uterine apla-
sia. The sequencing of the WNT4  gene in 19 MRKH
patients has confirmed that this gene is not involved in
MRKH syndrome [83]. Finally, the very recent report on a
second patient bearing another WNT4 mutation has led
to the conclusion that WNT4 deficiency is responsible for
a clinical phenotype distinct from the classic MRKH syn-
drome [81]. This new syndrome due to WNT4 mutations
in XX women and characterized by absence of Müllerian
ducts derivatives, hyperandrogenism and kidney optional
adysplasia [80,81], is close but different from MRKH syn-
drome; therefore, it should be referred to as a proper
name, such as "WNT4 syndrome" or "WNT4 defects" and
be consequently recorded under an appropriate OMIM
number. This latter could well be 277000 if amended;
OMIM 601076 would then be restricted to MRKH type I
and II or MURCS.
The TCF2 gene (formerly v-HNF1 or HNF-1β) was origi-
nally found associated with MODY-type diabetes [84] and
with diabetes mellitus, renal cysts and other renal devel-
opmental disorders [85,86]. Interestingly, genital malfor-
mations such as bicornuate uterus [87], uterus didelphys
[87] and Müllerian aplasia [88] (OMIM 158330) were
occasionally found associated with renal anomalies in
some familial aggregates showing mutations within the
TCF2 gene. Defects of this later gene can thus account for
some rare cases of Müllerian malformations, including
aplasia, making this gene one of the candidates for
MRKH, but restricted to familial cases with renal and/or
diabetes history. Finally the hypothesis of polygenic/mul-
tifactorial causes for MRKH syndrome has been reinforced
by recent findings, in adults, of interstitial and terminal
deletions involving chromosomes 22 [89] and 4 [90],
respectively. However, the large number of genes included
in each of these deletions has not allowed yet to precise
any specific gene responsible for the syndrome. Only
analysis of large cohorts of MRKH patients will certainly
help to delineate new candidate genes and to establish
phenotype/genotype correlations necessary for the genetic
diagnosis of the syndrome.
Diagnostic methods
Transabdominal ultrasonography
Transabdominal ultrasonograph is a simple and noninva-
sive method, and must be the first investigation in evalu-
ating patients with suspected Müllerian aplasia. This
technique reveals an absence of the uterine structure
between the bladder and the rectum. However, a quadran-
gular retro-vesical structure may be wrongly identified as
a hypoplasic or juvenile uterus: this fact corresponds to
the vestigial lamina located underneath the peritoneal
fold, itself situated transversally to the posterior side of the
bladder, where uterosacral ligaments attach. Since the ves-
tigial lamina shows no cavity, there is no evidence of a
hyperechogenic line, which normally corresponds to the
uterine mucous membrane [91]. Finally, renal malforma-
tions must be systematically evaluated during this scan.
Magnetic resonance imaging (MRI)
MRI is a non-invasive technique that provides a more sen-
sitive and more specific means of diagnosis than ultra-
sonography. It should be performed when
ultrasonographic findings are inconclusive or incomplete,
since failure to clearly identify the uterus or Müllerian
rudiments or ovaries does not necessarily imply their
absence. MRI allows an accurate evaluation of the uterine
aplasia, as well as a clear visualization of the rudimentary
horns and ovaries [92,93]. The uterine aplasia is best char-
acterized on sagittal images, while vaginal aplasia is best
evidenced on transverse images [94]. Moreover, MRI can
be used at the same time to search for associated renal and
skeletal malformations.
Celioscopy
This is an invasive technique requiring hospitalization
and anesthesia. It is performed in cases of doubtful diag-
nosis after ultrasonography and/or MRI. Celioscopy is
nowadays mainly reserved for women in whom interven-
tional therapy is likely to be undertaken (construction of
a neo-vagina: see Treatment section). It defines the precise
anatomical location and abnormalities of the uterus, the
possible tubar remnants, the vestigial lamina and the ova-
ries.Orphanet Journal of Rare Diseases 2007, 2:13 http://www.OJRD.com/content/2/1/13
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Biological status
The karyotype of MRKH patients is always 46, XX with no
visible chromosome modification. The endocrine balance
(plasmatic follicle stimulating hormone (FSH), luteiniz-
ing hormone (LH) and 17ß-oestradiol) is normal and
provides evidence of normal and functional ovaries
[15,95]. There is no external or endocrine sign of hyperan-
drogenism, as shown by a normal plasmatic level of testo-
sterone, delta-4-androstenedione, 17-
hydroxyprogesterone and dehydroepiandrosterone.
Once MRKH syndrome is diagnosed, a full check-up must
be undertaken to search for associated malformations.
Since renal and skeletal abnormalities may not be symp-
tomatic, it is necessary to perform at least transabdominal
ultrasonography and spine radiography. In case of suspi-
cion of hearing impairment and/or a cardiac anomaly,
complementary audiogram and/or heart echography
must also be carried out.
Moreover, when diagnosing an MRKH syndrome in a
patient, it is important to consider the family history.
Depending on the background, investigation of the
patient's relatives may also be recommended, mainly for
renal but also for skeletal malformations.
Differential diagnosis
Differential diagnosis of Müllerian aplasia includes
patients presenting with primary amenorrhea and with
normal secondary sexual characteristics (Table 1). This
should first lead to exclusion of gonadal dysgenesis. The
differential diagnosis includes congenital absence of
uterus and vagina (aplasia or agenesis), isolated vaginal
atresia and androgen insensitivity [96,97]. Transverse vag-
inal septum and imperforate hymen, which can be ini-
tially misleading, are not included. Indeed, patients with
these latter conditions have normal cervix and uterus,
both of which are palpable on rectal examination. Ultra-
sonography can be used to define the Müllerian structures
in infrequent cases where palpation is unrevealing.
Isolated vaginal atresia
Questioning will generally reveal pelvic pain in associa-
tion with cryptomenorrhea on physical examination. Vag-
inal atresia is found in various syndromes, mainly Winter
syndrome (characterized by renal, genital, and middle ear
anomalies) (OMIM 267400) [98,99], and McKusick-
Kaufman syndrome, which associates hydrometrocolpos,
postaxial polydactyly and congenital heart malformation
(OMIM 236700) and is due to mutations in the MKKS
gene located on chromosome 20p12 [100]. It is notewor-
thy that while partial or total Müllerian aplasia found in
MRKH syndrome confers irreversible sterility, vaginal
atresia can be surgically corrected to permit pregnancy
[99].
WNT4 defects
To date, only two cases of WNT4 defects have been pub-
lished [80,81]. This condition is similar but distinct from
MRKH syndrome (see Etiology section) and may therefore
lead to confusion. It seems quite clear that other cases will
soon be reported in the literature, making it important to
include this new syndrome in the differential diagnosis of
MRKH/MURCS. Evidence of hyperandrogenism in
women presenting with normal female phenotype should
then initially direct the clinicians to suspect WNT4 as a
cause.
Androgen insensitivity syndrome (AIS)
AIS, also called testicular feminization syndrome (TFM),
(OMIM 300068), is a male pseuhermaphroditism disor-
der caused by mutations in the gene for the androgen
receptor [101]. AIS is an X-linked recessive disorder in
which affected males have female external genitalia,
female breast development, blind vagina, absent uterus
and female adnexa, and abdominal or inguinal testes. Par-
tial androgen insensitivity results in hypospadias and
micropenis with gynecomastia, thus the syndrome cannot
be confused with MRKH syndrome.
Müllerian derivative aplasia
Müllerian derivative aplasia, which may be suggestive of
MRKH syndrome, has been described in association with
Table 1: Summary of differential diagnosis between MRKH syndrome and isolated vaginal atresia, WNT4 syndrome, and androgen 
insensitivity syndrome.
MRKH/MURCS Isolated vaginal atresia WNT4 syndrome Androgen insensitivity
Upper vagina Absent Variable Absent Absent
Uterus Absent Present Absent Absent
Gonads Ovary Ovary Masculinized ovary Testis
Breast development Normal Normal Normal Normal
Pubic-hair 
development
Normal Normal Normal Sparse
Hyperandrogenism No No Yes No
Karyotype 46, XX 46, XX 46, XX 46, XYOrphanet Journal of Rare Diseases 2007, 2:13 http://www.OJRD.com/content/2/1/13
Page 6 of 9
(page number not for citation purposes)
gonadal dysgenesis. In this case, patients showed abnor-
mal karyotypes, always involving the X chromosome,
such as mosaicisms 45, X/46, X, dic(X) [27], 46, XX/45, X0
[102], 46, XX/47, XXX [103] or rearrangements/deletions
such as 46, X, del(X)(pter-q22) [104], 46, X, i(Xq) [105]
or more complex karyotypes [12]. However, MRKH syn-
drome does not seem to be an X-linked trait and it there-
fore appears that the X chromosome carries one or several
genes involved in very early differentiation of at least both
gonads and Müllerian ducts.
Management including treatment
Young women diagnosed with MRKH syndrome suffer
from extreme anxiety and very high psychological distress
when they are told they have no uterus and vagina. Thus,
it is recommended that the patient and family attend
counseling before and throughout treatment. Group pro-
grams [106] and/or MRKH patients associations are also
of great help. Indeed, psychological adjustment as well as
medical attitude will be of great consequence for future
decisions of creation of a neo-vagina and management of
sterility [2,70,106].
Treatment of utero-vaginal aplasia
Treatment consisting of creating a neovagina must be
offered to patients only when they are ready to start sexual
activity and also when they are emotionally mature. Treat-
ment may be either surgical or nonsurgical, but the cho-
sen method needs to be tailored to the individual needs,
motivation of the patient and the options available
[2,70,96,107]. There are two main types of procedure. The
first one consists of the creation of a new cavity and can be
nonsurgical or surgical. The second is vaginal replacement
with a pre-existing canal lined with a mucous membrane
(a segment of bowel).
Nonsurgical creation of a neovagina
The most commonly used nonsurgical procedure is
Franck's dilator method. It involves the application, first
by the clinician and then by the patient herself, of vaginal
dilators (Hegar candles), progressively increasing in
length and diameter. Dilators are placed on the perineal
dimple for at least 20 minutes a day. A variation of this
procedure, using a bicycle stool, was described by Ingram
[108]. The whole process takes between six weeks and sev-
eral months, with a success rate varying from 78% [109]
to 92% [110]. Complications are rare; they generally con-
sist of urethritis, cystitis, vesico- or retro-vaginal fistula
and secondary prolapse. As this nonoperative approach is
noninvasive and often successful, it is recommended as a
first-line therapy. However, it can be applied only when
the vaginal dimple is deep enough (2–4 cm).
Surgical creation of a neovagina
A number of techniques are appropriate for the correction
of vaginal agenesis and there is no consensus regarding
the best option, the approach being most often based on
the surgeon's experience. Three methods are currently in
use:
- The Abbe-McIndoe operation: this involves the dissec-
tion of a space between the rectum and the bladder, place-
ment of a mold covered with a skin graft into the space,
and diligent postoperative vaginal dilatation. Modifica-
tions of this procedure rely on spontaneous epithelializa-
tion or on the use of different materials such as
peritoneum [111], minora labia grafting, or synthetic
materials [112,113].
- The Vecchietti operation is a mixture of surgical and non-
surgical methods. It has been performed frequently in
Europe over the last 20 years [70]. This procedure involves
the creation of a neovagina via dilatation with a traction
device attached to the abdomen, sutures placed subperito-
neally by laparotomy, and a plastic olive placed in the vag-
inal dimple. A laparoscopic or celioscopic modification is
often preferred and leads to comparable results [114].
- Sigmoidal colpoplasty: this technique involves vaginal
replacement or creation of a neovagina by grafting a 12–
18 cm long segment of sigmoid [115], providing that a
single and/or left pelvic kidney does not impair the proce-
dure. Sigmoidal colpoplasty is believed to be an efficient
procedure giving excellent results, although complete ade-
quacy for coital function often requires prolonged care
and support [116].
In conclusion, nonsurgical creation of a neovagina should
be the first-line approach, if suitable. When a surgical
approach is chosen, the surgeon must be experienced with
the procedure. Clinical follow-up and also regular inter-
course take place in the mid- and long-term successful
process. Above all, a careful psychological preparation of
the patient before any treatment or intervention is of
major importance.
Ultimately, infertility will be the most difficult aspect of
the disorder for the patient to accept. Nowadays medical
technologies allow, in many countries, women to appeal
for in vitro fertilization of their own eggs and to use surro-
gate pregnancy [96]. However, the risk for transmission of
the disease cannot be accurately evaluated, since very little
is currently known about genetics of the MRKH syn-
drome. This strengthens the need for more research in the
field.Orphanet Journal of Rare Diseases 2007, 2:13 http://www.OJRD.com/content/2/1/13
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Unresolved questions
Can an equivalent MRKH syndrome or MURCS manifest
in the male? Striking similarities found in male patients
have raised the question [117,118]. Combinations of
Wolffian duct agenesis or severe hypoplasia with or with-
out renal and/or skeletal anomalies and/or hearing
impairment have been described and include congenital
unilateral renal agenesis associated with ipsilateral agene-
sis of the vas deferens [9,119,120], primary infertility due
to azoospermia associated with Klippel-Feil anomaly
[117], and segmentation abnormalities of the cervicotho-
racic spine and hearing impairment [121,122]. Interest-
ingly, such male cases were found in families with female
patients with MRKH syndrome [9]. It is noteworthy that
in azoospermic patients, the infertility seems to be attrib-
utable to uni- or bilateral defects of vas deferens develop-
ment, ranging from hypoplasia [117] to agenesis
[120,122] and leading to a so-called obstructive azoosper-
mia.
Since the designation MURCS association cannot apply to
males, it was suggested that the male counterpart ARCS
(Azoospermia, Renal anomalies, Cervicothoracic Spine
dysplasia) would be a more suitable designation for this
condition in males [121,122]. The acronym GRES (Geni-
tal Renal Ear Skeletal), which applies to both sexes [10],
would be even more appropriate, especially when MURCS
and ARCS are found together in the same family [9].
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